Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

Ben De Pauw, Thomas J. Walsh, J. Peter Donnelly, David A. Stevens, John E. Edwards, Thierry Calandra, Peter G. Pappas, Johan Maertens, Olivier Lortholary, Carol A. Kauffman, David W. Denning, Thomas F Patterson, Georg Maschmeyer, Jacques Bille, William E. Dismukes, Raoul Herbrecht, William W. Hope, Christopher C. Kibbler, Bart Jan Kullberg, Kieren A. MarrPatricia Muñoz, Frank C. Odds, John R. Perfect, Angela Restrepo, Markus Ruhnke, Brahm H. Segal, Jack D. Sobel, Tania C. Sorrell, Claudio Viscoli, John R. Wingard, Theoklis Zaoutis, John E. Bennett

Research output: Contribution to journalArticle

3068 Citations (Scopus)

Abstract

Background. Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies. Methods. After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved. Results. The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only. Conclusions. These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.

Original languageEnglish (US)
Pages (from-to)1813-1821
Number of pages9
JournalClinical Infectious Diseases
Volume46
Issue number12
DOIs
StatePublished - Jun 15 2008

Fingerprint

National Institute of Allergy and Infectious Diseases (U.S.)
Sodium Glutamate
Mycoses
Organizations
Research
Immunocompromised Host
Neoplasms
Therapeutics
Manuscripts
Infection
Referral and Consultation
Invasive Fungal Infections
Technology
Morbidity
Mortality

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Medicine(all)

Cite this

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. / De Pauw, Ben; Walsh, Thomas J.; Donnelly, J. Peter; Stevens, David A.; Edwards, John E.; Calandra, Thierry; Pappas, Peter G.; Maertens, Johan; Lortholary, Olivier; Kauffman, Carol A.; Denning, David W.; Patterson, Thomas F; Maschmeyer, Georg; Bille, Jacques; Dismukes, William E.; Herbrecht, Raoul; Hope, William W.; Kibbler, Christopher C.; Kullberg, Bart Jan; Marr, Kieren A.; Muñoz, Patricia; Odds, Frank C.; Perfect, John R.; Restrepo, Angela; Ruhnke, Markus; Segal, Brahm H.; Sobel, Jack D.; Sorrell, Tania C.; Viscoli, Claudio; Wingard, John R.; Zaoutis, Theoklis; Bennett, John E.

In: Clinical Infectious Diseases, Vol. 46, No. 12, 15.06.2008, p. 1813-1821.

Research output: Contribution to journalArticle

De Pauw, B, Walsh, TJ, Donnelly, JP, Stevens, DA, Edwards, JE, Calandra, T, Pappas, PG, Maertens, J, Lortholary, O, Kauffman, CA, Denning, DW, Patterson, TF, Maschmeyer, G, Bille, J, Dismukes, WE, Herbrecht, R, Hope, WW, Kibbler, CC, Kullberg, BJ, Marr, KA, Muñoz, P, Odds, FC, Perfect, JR, Restrepo, A, Ruhnke, M, Segal, BH, Sobel, JD, Sorrell, TC, Viscoli, C, Wingard, JR, Zaoutis, T & Bennett, JE 2008, 'Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group', Clinical Infectious Diseases, vol. 46, no. 12, pp. 1813-1821. https://doi.org/10.1086/588660
De Pauw, Ben ; Walsh, Thomas J. ; Donnelly, J. Peter ; Stevens, David A. ; Edwards, John E. ; Calandra, Thierry ; Pappas, Peter G. ; Maertens, Johan ; Lortholary, Olivier ; Kauffman, Carol A. ; Denning, David W. ; Patterson, Thomas F ; Maschmeyer, Georg ; Bille, Jacques ; Dismukes, William E. ; Herbrecht, Raoul ; Hope, William W. ; Kibbler, Christopher C. ; Kullberg, Bart Jan ; Marr, Kieren A. ; Muñoz, Patricia ; Odds, Frank C. ; Perfect, John R. ; Restrepo, Angela ; Ruhnke, Markus ; Segal, Brahm H. ; Sobel, Jack D. ; Sorrell, Tania C. ; Viscoli, Claudio ; Wingard, John R. ; Zaoutis, Theoklis ; Bennett, John E. / Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. In: Clinical Infectious Diseases. 2008 ; Vol. 46, No. 12. pp. 1813-1821.
@article{b173d4c008cf48a3aee94d3ca5162486,
title = "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group",
abstract = "Background. Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies. Methods. After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved. Results. The revised definitions retain the original classifications of {"}proven,{"} {"}probable,{"} and {"}possible{"} invasive fungal disease, but the definition of {"}probable{"} has been expanded, whereas the scope of the category {"}possible{"} has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only. Conclusions. These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.",
author = "{De Pauw}, Ben and Walsh, {Thomas J.} and Donnelly, {J. Peter} and Stevens, {David A.} and Edwards, {John E.} and Thierry Calandra and Pappas, {Peter G.} and Johan Maertens and Olivier Lortholary and Kauffman, {Carol A.} and Denning, {David W.} and Patterson, {Thomas F} and Georg Maschmeyer and Jacques Bille and Dismukes, {William E.} and Raoul Herbrecht and Hope, {William W.} and Kibbler, {Christopher C.} and Kullberg, {Bart Jan} and Marr, {Kieren A.} and Patricia Mu{\~n}oz and Odds, {Frank C.} and Perfect, {John R.} and Angela Restrepo and Markus Ruhnke and Segal, {Brahm H.} and Sobel, {Jack D.} and Sorrell, {Tania C.} and Claudio Viscoli and Wingard, {John R.} and Theoklis Zaoutis and Bennett, {John E.}",
year = "2008",
month = "6",
day = "15",
doi = "10.1086/588660",
language = "English (US)",
volume = "46",
pages = "1813--1821",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

AU - De Pauw, Ben

AU - Walsh, Thomas J.

AU - Donnelly, J. Peter

AU - Stevens, David A.

AU - Edwards, John E.

AU - Calandra, Thierry

AU - Pappas, Peter G.

AU - Maertens, Johan

AU - Lortholary, Olivier

AU - Kauffman, Carol A.

AU - Denning, David W.

AU - Patterson, Thomas F

AU - Maschmeyer, Georg

AU - Bille, Jacques

AU - Dismukes, William E.

AU - Herbrecht, Raoul

AU - Hope, William W.

AU - Kibbler, Christopher C.

AU - Kullberg, Bart Jan

AU - Marr, Kieren A.

AU - Muñoz, Patricia

AU - Odds, Frank C.

AU - Perfect, John R.

AU - Restrepo, Angela

AU - Ruhnke, Markus

AU - Segal, Brahm H.

AU - Sobel, Jack D.

AU - Sorrell, Tania C.

AU - Viscoli, Claudio

AU - Wingard, John R.

AU - Zaoutis, Theoklis

AU - Bennett, John E.

PY - 2008/6/15

Y1 - 2008/6/15

N2 - Background. Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies. Methods. After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved. Results. The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only. Conclusions. These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.

AB - Background. Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies. Methods. After the introduction of the original European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition of areas in need of improvement led to a revision of this document. The revision process started with a meeting of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public comment, and then the manuscript was prepared and approved. Results. The revised definitions retain the original classifications of "proven," "probable," and "possible" invasive fungal disease, but the definition of "probable" has been expanded, whereas the scope of the category "possible" has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for immunocompromised patients only. Conclusions. These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients.

UR - http://www.scopus.com/inward/record.url?scp=46249126149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249126149&partnerID=8YFLogxK

U2 - 10.1086/588660

DO - 10.1086/588660

M3 - Article

C2 - 18462102

AN - SCOPUS:46249126149

VL - 46

SP - 1813

EP - 1821

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 12

ER -